Want to join the conversation?
Under the Generics segment, sales in North America were approx. $1.1Bil in 3Q15, up 29% YoverY on a constant currency basis. $MYL's legacy business grew by 24% as a result of continued strong performance of sales from new products and higher volumes on existing products, offset by lower net pricing. $MYL launched 14 new products in the US in 3Q15.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)